Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

9.1%

1 terminated/withdrawn out of 11 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

9%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(40.0%)
Phase 1
3(30.0%)
N/A
2(20.0%)
Phase 3
1(10.0%)
10Total
Phase 2(4)
Phase 1(3)
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT07001618Phase 2Not Yet Recruiting

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Role: collaborator

NCT05889572Phase 1Completed

Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis

Role: lead

NCT05762211Phase 2Recruiting

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

Role: lead

NCT04769895Phase 3Active Not Recruiting

MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients

Role: lead

NCT04768907Unknown

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

Role: lead

NCT05017688Not ApplicableUnknown

Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013

Role: lead

NCT04150393Phase 1Completed

Safety and Tolerability Evaluation of MaaT033

Role: lead

NCT03359980Phase 2Completed

Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer

Role: lead

NCT02928523Phase 1Completed

PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

Role: lead

NCT03350178Phase 2Terminated

Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

Role: lead

NCT03011502Not ApplicableCompleted

InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS

Role: lead

All 11 trials loaded